acute coronary syndrome (ACS) 4–5, 45, 106, 130
age 8, 66
angina pectoris 21
antidepressants
  behaviour, influence on 134–5
  CBT studies, use in 152, 155–6
  and CRP levels 44
  drug interactions 138
  mechanisms involved 134–5
  and periodontal disease 104
studies
  community vs. clinical samples 125–6
  CREATE study 157–8
  epidemiological 132–3
  on influence on morbidity/mortality 128–30, 129, 131, 132–3
  problems faced 127, 133
  SADHART study 6, 127–9, 129, 130, 135–6, 137
  on safety 127–8
  treatment, implementing 133–8
anxiety 12, 58, 62, 69, 70
atherosclerosis 13, 23, 30, 44, 57–8, 59
attitudes, patients’ 107, 109, 114
autonomic nervous system dysregulation 40–2, 47
Baker, R.A. 13
Bane, C. 109
Barefoot, J.C. 7
baroreflex sensitivity 41
Beck, A.T. 147–8, 150, 154
Beck, J.S. 149–50, 154
behaviour modification 147
behaviour therapy 147–8
  see also cognitive behaviour therapy
behavioural activation therapy 161–2
beliefs, patients’ 107, 109, 114
bivariate heritability see heritability (twin) studies
blood clotting 42–4
blood pressure 62, 82
Blumenthal, J.A. 13
body mass index 62
INDEX

Borowicz, L. Jr.  12
Brutsaert, D.L.  2, 6
Burg, M.M.  13
Bypassing the Blues study  137
C-reactive protein (CRP)  44–6, 104
Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) study  157–9
Carney, R.M.  6
catecholamine levels  46–7
CD40 ligand  42–3
Chao, J.  107
checklist for clinicians  113–15
chest pain  5, 12–13
citalopram  132, 138, 157–8
clotting, blood  42–4
cognitive behaviour therapy  147–8
aims of  150
ENRICHID trial  129–30, 149–53
vs. interpersonal psychotherapy  158–9
post-CABG treatment  153–6
vs. problem-solving therapy  160
vs. supportive stress management  153–6
telephone-delivered  162
Cognitive therapy for challenging problems (J.S. Beck)  154
Cognitive therapy (J.S. Beck)  154
Cognitive therapy of depression (A.T. Beck)  147–8, 154
collaborative care  136–7, 162
congestive heart failure (CHF)  23–5, 26–9, 39
Connerney, I.  12
coping  154, 159–60
coronary artery bypass grafting (CABG)  8, 9–11, 12–14, 153–6
coronary microcirculation  67
Coronary Psychosocial Evaluation Studies (COPES) project  160, 162
cortisol levels  46–7, 111
cytokines  44–6, 58–9, 81, 104
Denollet, J.  2, 6
depression and CAD development  14, 15–19, 20–3
incident vs. recurrent  5
recognizing, importance of  30, 113–15, 136, 139
recurrence of  13, 150
screening for  136
and stable CAD  6–8
time course of  4, 7, 12–13
Depression after Myocardial Infarction study  4
diabetes  62, 82, 101, 107, 109
distress, emotional  8, 148, 160
dopamine  103
drug interactions  138
D’Zurilla, T.J.  159
endothelial dysfunction  42, 43–4, 46, 47
Enhancing Recovery In Coronary Heart Disease (ENRICHID)  4–5, 129–30, 131, 132, 138, 149–53
environmental influences  58, 65, 66, 67
equal environment assumption  61
family studies  62, 67, 68
fat  44, 47
fatty acids, polyunsaturated (PUFAs)  46
fibrinogen  45, 68, 104
Finnish cohort study  133
fluoxetine  128, 138
INDEX
mortality rates
antidepressants, impact
of 128–30, 131, 132–3
and anxiety 12
congestive heart failure 24
and heart rate variability 41
impact of depression 7, 14, 39, 135–6
ACS patients 4–5
changes over time 7
CHF patients 24–5
gender differences 21
major vs. minor depression 4, 7
post-CABG 13–14
post-MI 2, 3, 4, 5–6, 126, 126
and patients’ attitudes 107
psychotherapy, impact of 151–2
and social isolation 109–10
Murberg, T.A. 24
Myocardial Infarction and Depression-Intervention Trial (MIND-IT) 132
myocardial infarction (MI)
depression, impact of 2, 3, 4–6, 39, 126, 126
and depression rates 2, 22
and HRV 41
mortality rates 2, 3, 4, 5–6, 126, 126
post-MI psychotherapy 149–53
and sleep disturbance 100
nervous system 40–2, 46–8, 111
neuroendocrine abnormalities 46–7
neuronal nicotinic acetylcholine receptors (nAChRs) 103
Nezu, A.M. 159
nicotine 69, 103
nitric oxide production 43–4
noradrenaline levels 40, 103, 111
optimism 12
Parakh, K. 6
paroxetine 43–4, 138
Patient Health Questionnaires (PHQs) 136
periodontal disease 104
Peterson, J.C. 12, 13
physical inactivity 62, 69–70, 102, 114
physicians, educating about depression 139
platelet activation 42–3, 46
pleiotropy, genetic see genetic pleiotropy
polyunsaturated fatty acids (PUFAs) 46
predictors
of cardiac events 6, 12–13, 45, 58, 112, 135–6
of mortality 12, 24, 40–1
Prevention of Suicide in Primary Care Elderly: Collaborative Trial (PROSPECT) 137
problem orientation 159
problem-solving therapy 159–60
procoagulative factors 43
psychotherapy 133–4, 145–7
care choices 161–2
cognitive behaviour see cognitive behaviour therapy
future research directions 161–3
interpersonal psychotherapy 156–9
problem-solving therapy 159–60
problems identified 161
QT interval variability 41–2
recurrence of cardiac events 4, 5, 7–8, 12, 24
SSRIs, impact of 128–9, 129
relationships
between depression and atherosclerosis 30, 57–8
between depression and cardiovascular disease 39
between depression and heart disease 57–8, 134
behavioural mechanisms 100–6, 101, 113
biological mechanisms 47–8, 48
causal hypothesis 65–6
biological mechanisms 47–8, 48
genetic mechanisms 89
psychological mechanisms 107, 108, 109–13
between depression and physical inactivity 102
risk factors for atherosclerosis 46
for cardiovascular disease 100–1, 102
for congestive heart failure 24
for coronary artery disease 14, 20–3
autonomic nervous system dysregulation 40–2
blood clotting mechanisms 42–4
endothelial dysfunction 43
inflammation 44–6
neuroendocrine abnormalities 46–7
smoking 103–4
for depression 23, 39, 57–8
environmental vs. genetic 65–6
genes associated with 82, 83–7
heritability of 62–3, 66–70, 71–5
Rutledge, T. 25
Saur, C.D. 12
Scheier, M.F. 8
Scherrrer, J.F. 66
Schleifer, S.J. 2

Screening Across the Lifespan Twin (SALT) study 66
selective serotonin reuptake inhibitors (SSRIs) 42, 43–4, 139
ENRICHD trial 129–30, 132, 138
impact on morbidity/mortality 128–30, 129, 131, 132–3
implementing use of 133–8
SADHART study 128–9, 129
self-efficacy 112–13, 114–15
serotonin 42, 80, 103
see also selective serotonin reuptake inhibitors (SSRIs)
serotonin transporter gene 80
sertraline 6, 128, 137, 138
Sertraline AntiDepressant Heart Attack Trial (SADHART) 6, 127–9, 129, 130, 135–6, 137
Skala, J.A. 154
Skinner, B.F. 147
sleep disturbance 100–1, 113–14
smoking 62, 69, 103–4, 114
social isolation and support 109–10, 114, 152–3, 158–9
SSRIs see selective serotonin reuptake inhibitors (SSRIs)
stepped care 162
The Stockholm Heart Epidemiology Program (SHEEP) study 22
stress 48, 80, 104, 110–12
stress management, supportive (SSM) 153–6
structural equation modelling 60, 65–6, 107, 109
Su, S. 65, 69
suicide 133
support, emotional 24
supportive stress management (SSM) 153–6
Systolic Hypertension in the Elderly Program 8
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>thrombotic mechanisms</td>
<td>42–4</td>
</tr>
<tr>
<td>treatment, adherence to</td>
<td>104–6, 107, 109, 114, 134–5</td>
</tr>
<tr>
<td>Treatment of Depression</td>
<td></td>
</tr>
<tr>
<td>Collaborative Research Program (TDCRP)</td>
<td>157</td>
</tr>
<tr>
<td>tricyclics</td>
<td>127, 133, 138</td>
</tr>
<tr>
<td>Tully, P.J.</td>
<td>12</td>
</tr>
<tr>
<td>tumor necrosis factor (TNF)-α</td>
<td>44–6, 68, 81, 88</td>
</tr>
<tr>
<td>twin studies <em>see</em> heritability (twin)</td>
<td></td>
</tr>
<tr>
<td>studies</td>
<td></td>
</tr>
<tr>
<td>US Preventive Services Task Force report</td>
<td>138</td>
</tr>
<tr>
<td>Vaccarino, V.</td>
<td>24, 45, 67, 68</td>
</tr>
<tr>
<td>vascular depression hypothesis</td>
<td>13, 57–8</td>
</tr>
<tr>
<td>Weissman, M.</td>
<td>156</td>
</tr>
<tr>
<td>Wellenium, G.A.</td>
<td>13</td>
</tr>
<tr>
<td>Women’s Ischaemia Syndrome Evaluation (WISE) study</td>
<td>21</td>
</tr>
</tbody>
</table>